For the quarter ended September 2025, 10x Genomics (TXG) reported revenue of $149 million, down 1.8% over the same period last year. EPS came in at -$0.22, compared to -$0.30 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $142.39 million, representing a surprise of +4.64%. The company delivered an EPS surprise of +18.52%, with the consensus EPS estimate being -$0.27.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues- Services: $8.13 million versus $7.86 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +27.1% change.
- Revenues- Instruments: $12 million versus the three-analyst average estimate of $14.06 million. The reported number represents a year-over-year change of -37%.
- Revenues- Instruments- Chromium: $4.93 million versus $5.36 million estimated by three analysts on average.
- Revenues- Consumables- Chromium: $92.52 million versus the three-analyst average estimate of $85.29 million.
- Revenues- Consumables- Spatial: $35.37 million compared to the $35.06 million average estimate based on three analysts.
- Revenues- Consumables: $127.89 million compared to the $120.35 million average estimate based on three analysts. The reported number represents a change of +1.3% year over year.
- Revenues- Instruments- Spatial: $7.07 million compared to the $8.71 million average estimate based on three analysts.
View all Key Company Metrics for 10x Genomics here>>>
Shares of 10x Genomics have returned +11.8% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up10x Genomics (TXG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
